Search Results
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Filgrastim
Filgrastim is FDA approved to
Sargramostim
Sargramostim is FDA approved
Gilteritinib
Gilteritinib is a indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Tisagenlecleucel
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
LLS and Burlington Celebrate 20 years of Fighting Blood Cancer Together!
The Leukemia & Lymphoma Society (LLS) and Burlington Stores are marking two decades of an incredible partnership this year. With Burlington’s help, LLS has been able to provide free information, education, and 1:1 support for hundreds of thousands of blood cancer patients. And we’re still going strong. Continuing the momentum, Burlington is committed to helping support lifesaving research for the LLS Children’s Initiative.
Loss of the non-canonical BAF complex as a driver and therapeutic target in SF3B1-mutant MDS and leukemia
The most common cause of MDS is a genetic mutation occurring in blood cells that affects a process called “RNA splicing”. The most commonly mutated RNA splicing factor gene is called SF3B1. We now know that many patients with MDS carry mutations in SF3B1 but we do not know why these mutations cause disease. Dr. Bradley proposes to determine how mutations in SF3B1 cause MDS and potentially create new opportunities for treating this disease.Supporting Lifesaving Medicaid Expansion for Patients
On November 6, citizens in Idaho, Nebraska, and Utah approved ballot measures to expand Medicaid in their states. These landmark votes will close the coverage gap for more than 360,000 people in these states who earn too much to qualify for traditional Medicaid but not enough to get help with the cost of buying individual coverage.
Small Steps Make Big Impact for Moms In Training
Getting the courage to work out is often harder than the workout itself. This is especially true when fitness plans include goals that are hard to measure. Fortunately, through a special partnership with Fitbit, many women in The Leukemia & Lymphoma Society's (LLS) Moms In Training program are learning to better manage their workouts and track their progress.
Heart Disease in Lymphoma Survivors
Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.
A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas
In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."A New Meaning to Mother's Day
By Sarah
Ultra-Endurance Athlete Takes on 1000-Mile Iconic Race for Cancer Cures
52-year-old Steve Cannon from Iowa refers to himself as an adventurer, but when you look at his track record of accomplishments, media, spectators and fans across the country refer to him as a beast. He was the first-ever athlete to run around Lake Michigan and averaged a marathon a day for 40 straight days totaling 1,037 miles. He’s also completed a 350-mile bike ride and took on the world’s longest Kayak race – just to list a few.
Two Prominent Themes of 2020 Make an Appearance at #ASH20: Covid-19 and Racial Disparities
With the COVID-19 pandemic driving yet another science conference to the virtual world, it is fitting that the 62nd ASH Annual Meeting and Exposition officially kicked off today with a virtual fireside chat via live stream featuring none other than Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and a member of the administration’s coronavirus task force.
RESEARCH NOW: 9/11 AND BLOOD CANCER RISK IN FIRST RESPONDERS
All of us were impacted by the tragedy of September 11. For those who dedicated countless hours to rescue, recovery, and clean-up efforts, the effects of that devastating incident continue to be a challenge. Firefighters, police officers, emergency medics and others were exposed to harmful fumes and dust in the weeks and months following that disaster.